Open AccessAxitinib in Combination With Toripalimab, a Humanized Immunoglobulin G4 Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial
Author(s) -
Xinan Sheng,
Xieqiao Yan,
Zhihong Chen,
Lu Si,
Chuanliang Cui,
Bixia Tang,
Siming Li,
Lili Mao,
Bin Lian,
Xuan Wang,
Xue Bai,
Li Zhou,
Yan Kong,
Jie Dai,
Kai Wang,
Xiongwen Tang,
Hua-ning Zhou,
Hai Wu,
Hui Feng,
Sheng Yao,
Keith T. Flaherty,
Jun Guo
Publication year - 2019
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.19.00210
Subject(s) - medicine , axitinib , rash , adverse effect , gastroenterology , oncology , melanoma , pharmacodynamics , proteinuria , bevacizumab , chemotherapy , pharmacokinetics , cancer , sunitinib , cancer research , kidney
Metastatic mucosal melanoma responds poorly to anti-programmed cell death-1 (PD-1) monotherapy. Vascular endothelial growth factor (VEGF) has been shown to play an important immunosuppressive role in the tumor microenvironment. The combination of VEGF inhibition and PD-1 blockade provides therapeutic opportunities for patients refractory to either therapy alone.